Sionna Therapeutics (NASDAQ:SION) CFO Elena Ridloff Sells 748 Shares

Key Points

• Sionna Therapeutics CFO Elena Ridloff sold 748 shares at an average price of $25.18, decreasing her holdings to 47,368 shares valued at approximately $1.19 million.
• The company's stock price dropped 3.3% to $24.55, with a significant trading volume of 617,701 shares compared to an average of 193,090.
• Analysts have mixed views on the stock, with one upgrade to a "hold" rating and a target price of $36, while Raymond James set a "strong-buy" rating with a price target of $45.00.

Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report) CFO Elena Ridloff sold 748 shares of the business's stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $25.18, for a total value of $18,834.64. Following the sale, the chief financial officer owned 47,368 shares of the company's stock, valued at approximately $1,192,726.24. The trade was a 1.55% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Elena Ridloff also recently made the following trade(s):

• On Tuesday, September 2nd, Elena Ridloff sold 8,836 shares of Sionna Therapeutics stock. The shares were sold at an average price of $25.08, for a total value of $221,606.88.
• On Thursday, August 28th, Elena Ridloff sold 16,098 shares of Sionna Therapeutics stock. The shares were sold at an average price of $25.97, for a total value of $418,065.06.
• On Wednesday, August 27th, Elena Ridloff sold 3,618 shares of Sionna Therapeutics stock. The stock was sold at an average price of $25.10, for a total value of $90,811.80.
• On Tuesday, August 26th, Elena Ridloff sold 3,700 shares of Sionna Therapeutics stock. The stock was sold at an average price of $25.13, for a total value of $92,981.00.

Sionna Therapeutics Trading Down 3.3%

Shares of Sionna Therapeutics stock traded down $0.84 on Wednesday, reaching $24.55. 617,701 shares of the stock were exchanged, compared to its average volume of 193,090. Sionna Therapeutics, Inc. has a 1-year low of $7.26 and a 1-year high of $26.50. The business has a fifty day moving average price of $20.08 and a two-hundred day moving average price of $15.82.

Sionna Therapeutics (NASDAQ:SION - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.41) earnings per share for the quarter, beating analysts' consensus estimates of ($0.68) by $0.27.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets purchased a new position in shares of Sionna Therapeutics during the second quarter valued at $31,000. Police & Firemen s Retirement System of New Jersey purchased a new position in shares of Sionna Therapeutics during the second quarter valued at $45,000. Virtus Investment Advisers LLC purchased a new position in shares of Sionna Therapeutics during the second quarter valued at $96,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Sionna Therapeutics during the second quarter valued at $117,000. Finally, New York State Common Retirement Fund purchased a new position in shares of Sionna Therapeutics during the second quarter valued at $118,000.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Wall Street Zen upgraded Sionna Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 16th. Raymond James Financial initiated coverage on Sionna Therapeutics in a research note on Tuesday. They set a "strong-buy" rating and a $45.00 price objective for the company. Finally, Royal Bank Of Canada started coverage on Sionna Therapeutics in a research report on Wednesday. They issued a "sector perform" rating and a $22.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $36.00.

About Sionna Therapeutics

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.